Median Technologies announces the signing of a € 35 million finance contract with the European Investment Bank (EIB). This finance contract will enable Median Technologies to accelerate its investment program for the iBiopsy® imaging phenomics platform. Median expects the disbursement of the first tranche of € 15 million during the first semester of 2020.
Read moreMedian Technologies’ Q3 performance shows steady growth, validates the strategy adopted in 2018 (unaudited figures). As of September 30th, 2019, cumulated revenue of € 6.3 million, already matching total revenue made in 2018 – Q3 revenue of € 2.3 million, a steady increase over the last four quarters – Order backlog of € 35.9 million, up 17% since June 30th, 2019 – Cash and cash equivalents of € 8.3 million, an increase compared to June 30th, 2019
Read moreMedian Technologies reports its financial results for H1 2019. H1 revenue up 19.5% to € 4 million, driven by iCRO business, Order backlog up 30% to € 30.7 million, Significant decrease of operating expenses, Cash and cash equivalents of € 7.9 million
Read moreH1 2019 results validate the company’s 2018 strategic refocus. During the period, revenues increased by 19,6% to reach €4 million (€3.4 million in H1 2018). Net new booking reached €11 million and order backlog increased by 30% to €30.7 million (€23.7 million as of December 31, 2018). Cash and cash equivalents expected to be approximatively €7.9 million as of June 30, 2019, with significantly reduced burn rate.
Read moreTo download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]